Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate vs fluticasone furoate/umeclidinium/vilanterol
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Chronic Obstructive Pulmonary Disease
Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) · full Chronic Obstructive Pulmonary Disease pipeline
Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate · Trimbow
Rights held by Chiesi Farmaceutici; US product discontinued
NCT03197818 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial of 708 participants, with 353 receiving the named triple therapy and 355 receiving Symbicort. Both prespecified primary FEV1 comparisons at week 24 were statistically significant in favor of the triple therapy (p<0.001), and FEV1 is an accepted clinical lung-function endpoint for COPD.
Next expected readout: December 2026 · NCT05495698 (registry estimate)
No aligned efficacy figure on record for this race.
fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta
Marketed by GlaxoSmithKline
NCT02164513 · Phase 3 · completed
This was a large randomized, double-blind, active-controlled trial in 10,355 COPD patients at 971 sites in 37 countries; the primary endpoint, annual on-treatment moderate/severe exacerbation rate, is a hard clinical outcome, and triple therapy significantly reduced exacerbations versus both dual-therapy comparators (rate ratio 0.75 vs UMEC/VI and 0.85 vs FF/VI, both p<0.001).
Next expected readout: September 2027 · NCT07192016 (registry estimate)
Reported efficacy
Annual Rate of On-treatment Moderate/Severe Exacerbations Comparing FF/UMEC/VI With UMEC/VI and FF/VI (Up to Week 52): Annual rate of on-treatment moderate/severe exacerbations: FF/UMEC/VI 0.91/yr vs FF/VI 1.07/yr (rate ratio 0.85, 95% CI 0.80-0.90, 15% reduction, p<0.001) vs UMEC/VI 1.21/yr (rate ratio 0.75, 95% CI 0.70-0.81, 25% reduction, p<0.001) (met)
Result source: NCT02164513
Results for Chronic Obstructive Pulmonary Disease
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate | fluticasone furoate/umeclidinium/vilanterol |
|---|---|---|
| Moderate or severe exacerbations, annualised rate | —Not posted · NCT02579850 | 0.9 vs 1.1vs FF/VINCT021645132 other results
|
| Trough FEV1, change | —Not posted · NCT02579850 | 0.1 vs -0.0vs BUD/FORNCT0234516114 other results
|
| SGRQ total, change | —Not posted · NCT02579850 | -6.6 vs -4.3vs BUD/FORNCT023451613 other results
|
| TDI focal score | —Not posted · NCT02579850 | 2.3 vs 1.7vs BUD/FORNCT023451611 other result
|
Moderate or severe exacerbations, annualised rate
- Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate
- —Not posted · NCT02579850
- fluticasone furoate/umeclidinium/vilanterol
- 0.9 vs 1.1vs FF/VINCT02164513
2 other results
- 0.2 vs 0.3 NCT02345161
- 0.2 vs 0.4 NCT02345161
Trough FEV1, change
- Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate
- —Not posted · NCT02579850
- fluticasone furoate/umeclidinium/vilanterol
- 0.1 vs -0.0vs BUD/FORNCT02345161
14 other results
- 0.1 vs -0.1 NCT02345161
- 0.1 vs 0.1 NCT02729051
- 0.1 vs -0.0 NCT02164513
- 0.1 vs 0.0 NCT03474081
- 0.0 vs -0.0 NCT03478696
- 0.0 vs -0.0 NCT03478683
- 0.1 vs 0.0 NCT03474081
- 0.0 vs -0.0 NCT03478696
- 0.0 vs -0.0 NCT03478683
- 0.1 vs -0.0 NCT03474081
- 0.0 vs -0.0 NCT03478696
- 0.0 vs -0.0 NCT03478683
- 0.0 vs -0.0 NCT03478696
- 0.0 vs 0.0 NCT03478683
SGRQ total, change
- Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate
- —Not posted · NCT02579850
- fluticasone furoate/umeclidinium/vilanterol
- -6.6 vs -4.3vs BUD/FORNCT02345161
3 other results
- -4.6 vs -1.9 NCT02345161
- -5.5 vs -3.7 NCT02164513
- -5.8 vs -4.9 NCT02729051
TDI focal score
- Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate
- —Not posted · NCT02579850
- fluticasone furoate/umeclidinium/vilanterol
- 2.3 vs 1.7vs BUD/FORNCT02345161
1 other result
- 1.7 vs 1.4 NCT02345161
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate: registry results are on file for Chronic Obstructive Pulmonary Disease, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate: 0 of 4 rows · fluticasone furoate/umeclidinium/vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | fluticasone furoate/umeclidinium/vilanterol |
|---|---|
| Dropout rate | 10.5%FF/UMEC/VIa NCT02164513 · Phase 3 show 9 more results—100/62.5/25 NCT02164513 · Phase 3 4.9%100/62.5/25 µg NCT02345161 · Phase 3 6.1% NCT04923347 · Phase 4 · registry result, not featured evidence 9.5% NCT05535972 · Phase 4 · registry result, not featured evidence 3%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI NCT03467425 · Phase 4 · registry result, not featured evidence 4.3%100/62.5/25 mcg NCT03474081 · Phase 4 · registry result, not featured evidence 4.6%100/62.5/25 mcg NCT03478696 · Phase 4 · registry result, not featured evidence 3.6%100/62.5/25 mcg NCT03478683 · Phase 4 · registry result, not featured evidence 5.7%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence |
| Discontinued due to AEs | 3.9%FF/UMEC/VIa NCT02164513 · Phase 3 show 9 more results—100/62.5/25 NCT02164513 · Phase 3 1.8%100/62.5/25 µg NCT02345161 · Phase 3 — NCT04923347 · Phase 4 · registry result, not featured evidence 1.3% NCT05535972 · Phase 4 · registry result, not featured evidence 0.6%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI NCT03467425 · Phase 4 · registry result, not featured evidence 1.5%100/62.5/25 mcg NCT03474081 · Phase 4 · registry result, not featured evidence 0.3%100/62.5/25 mcg NCT03478696 · Phase 4 · registry result, not featured evidence 1.4%100/62.5/25 mcg NCT03478683 · Phase 4 · registry result, not featured evidence 4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence |
| Serious AEs | —FF/UMEC/VIa NCT02164513 · Phase 3 show 9 more results21.6%100/62.5/25 NCT02164513 · Phase 3 6.7%100/62.5/25 µg NCT02345161 · Phase 3 0.4% NCT04923347 · Phase 4 · registry result, not featured evidence 4.1% NCT05535972 · Phase 4 · registry result, not featured evidence 7.4%100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI NCT03467425 · Phase 4 · registry result, not featured evidence 3.3%100/62.5/25 mcg NCT03474081 · Phase 4 · registry result, not featured evidence 4.4%100/62.5/25 mcg NCT03478696 · Phase 4 · registry result, not featured evidence 8%100/62.5/25 mcg NCT03478683 · Phase 4 · registry result, not featured evidence 10.4%100/62.5/25 NCT02729051 · Phase 3 · registry result, not featured evidence |
| Most frequent reported AEs | 100/62.5/25a viral upper respiratory tract infection 12.5% upper respiratory tract infection 7.2% headache 5.6% NCT02164513 · Phase 3 show 8 more resultsdysphonia 0.4% abdominal discomfort 0.2% abdominal pain upper 0.2% NCT05535972 · Phase 4 · registry result, not featured evidence 100 mcg/62.5 mcg/25 mcg by ELLIPTA DPI dyspnoea 2.1% NCT03467425 · Phase 4 · registry result, not featured evidence 100/62.5/25 mcg headache 4.5% nasopharyngitis 4% NCT03474081 · Phase 4 · registry result, not featured evidence 100/62.5/25 mcg headache 3.6% nasopharyngitis 1.9% NCT03478696 · Phase 4 · registry result, not featured evidence 100/62.5/25 viral upper respiratory tract infection 10.6% headache 6.1% upper respiratory tract infection 3.4% NCT02729051 · Phase 3 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
fluticasone furoate/umeclidinium/vilanterol
show 2 more results
show 14 more results
show 3 more results
show 1 more result
show 1 more result
show 17 more results
show 1 more result
show 1 more result
+ 8 further endpoints in the CSV export.
Asthma
Shared mechanism: Glucocorticoid receptor / Beta-2 adrenergic receptor / Muscarinic M3 receptor (ICS/LABA/LAMA triple combination) · full Asthma pipeline
Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate · Trimbow
Rights held by Chiesi Farmaceutici; US product discontinued
NCT02676076 · Phase 3 · completed
This was a randomized, quadruple-blind, active-controlled trial with 1,155 randomized participants. Both prespecified primary endpoints were met: the triple therapy produced a significantly greater improvement in FEV1 and a significantly lower moderate/severe exacerbation rate than beclomethasone/formoterol alone.
Next expected readout: June 2028 · NCT07666490 (registry estimate)
No aligned efficacy figure on record for this race.
fluticasone furoate/umeclidinium/vilanterol · Trelegy Ellipta
Marketed by GlaxoSmithKline
NCT02924688 · Phase 3 · completed
This was a large (N=2,436) randomized, triple-blind, active-controlled Phase III trial comparing four fixed-dose combinations of fluticasone furoate/umeclidinium/vilanterol against two fluticasone furoate/vilanterol dual therapy controls in patients with inadequately controlled asthma. The primary endpoint, change from baseline in trough FEV1 at Week 24, was met for every pre-specified triple-therapy versus dual-therapy comparison, with all four least-squares mean differences favoring triple therapy and p<0.001. The combination of randomization, blinding, an active comparator, a large sample, a hard clinical endpoint, and a statistically significant primary result constitutes strong evidence.
Next expected readout: January 2027 · NCT05757102 (registry estimate)
Reported efficacy
Mean Change From Baseline in Trough Forced Expiratory Volume in 1 Second (FEV1) at Week 24 (Baseline (pre-dose at Day 1) and Week 24): Week 24 trough FEV1: FF/UMEC/VI vs FF/VI treatment differences 0.096 L (95% CI 0.052 to 0.139; p<0.001), 0.110 L (95% CI 0.066 to 0.153; p<0.001), 0.082 L (95% CI 0.039 to 0.125; p<0.001), and 0.092 L (95% CI 0.049 to 0.135; p<0.001). (met)
Result source: NCT02924688
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate | fluticasone furoate/umeclidinium/vilanterol |
|---|---|---|
| Severe exacerbations, annualised rate | —Trial running · NCT07546981 | —Trial running · NCT04651777 |
| Trough FEV1, change | —Trial running · NCT07546981 | 0.1 vs 0.1vs FF/VINCT029246885 other results
|
| ACQ-5, change | —Trial running · NCT07546981 | —Trial running · NCT04651777 |
| OCS dose reduction | —Trial running · NCT07546981 | —Trial running · NCT04651777 |
Severe exacerbations, annualised rate
- Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate
- —Trial running · NCT07546981
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
Trough FEV1, change
- Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate
- —Trial running · NCT07546981
- fluticasone furoate/umeclidinium/vilanterol
- 0.1 vs 0.1vs FF/VINCT02924688
5 other results
- 0.2 vs 0.1 NCT02924688
- 0.1 vs 0.1 NCT02924688
- 0.2 vs 0.1 NCT02924688
- 0.1 vs 0.1 NCT04937387
- 0.1 vs 0.1 NCT04937387
ACQ-5, change
- Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate
- —Trial running · NCT07546981
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
OCS dose reduction
- Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate
- —Trial running · NCT07546981
- fluticasone furoate/umeclidinium/vilanterol
- —Trial running · NCT04651777
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate: registry results are on file for Asthma, but their comparison mappings are not yet available.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate: 0 of 4 rows · fluticasone furoate/umeclidinium/vilanterol: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | fluticasone furoate/umeclidinium/vilanterol |
|---|---|
| Dropout rate | 7.7%100/31.25/25 mcga NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.9%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 3.4%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 0%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 11.1%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 7.3%200/62.5/25 mcg NCT03184987 · Phase 3 · combination |
| Discontinued due to AEs | 0.7%100/31.25/25 mcga NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results0.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0.5%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0.5%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 0%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 0%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 1.8%200/62.5/25 mcg NCT03184987 · Phase 3 · combination |
| Serious AEs | 4.4%100/31.25/25 mcga NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results5.7%200/31.25/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.7%100/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 5.1%200/62.5/25 mcg NCT02924688 · Phase 3 · combination · Asthma · phase 3 1.1%FF 200 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 3.3%FF 100 ug, UMEC 62.5 ug, VI 25 ug NCT04937387 · Phase 3 · Asthma · phase 3 2.1%100/62.5/25 mcg NCT03184987 · Phase 3 · combination 0%100/62.5/25 mcg to 200/62.5/25 mcg NCT03184987 · Phase 3 · combination 3.6%200/62.5/25 mcg NCT03184987 · Phase 3 · combination |
| Most frequent reported AEs | 100/31.25/25 mcga nasopharyngitis 13.8% headache 7.7% upper respiratory tract infection 5.9% NCT02924688 · Phase 3 · combination · Asthma · phase 3 show 8 more results200/31.25/25 mcg nasopharyngitis 12.6% headache 6.7% bronchitis 4% NCT02924688 · Phase 3 · combination · Asthma · phase 3 100/62.5/25 mcg nasopharyngitis 14.8% headache 8.9% bronchitis 3.7% NCT02924688 · Phase 3 · combination · Asthma · phase 3 200/62.5/25 mcg nasopharyngitis 12.5% bronchitis 5.4% headache 4.7% NCT02924688 · Phase 3 · combination · Asthma · phase 3 FF 200 ug, UMEC 62.5 ug, VI 25 ug covid-19 5.7% nasopharyngitis 4.5% upper respiratory tract infection 4.5% NCT04937387 · Phase 3 · Asthma · phase 3 FF 100 ug, UMEC 62.5 ug, VI 25 ug upper respiratory tract infection 7.8% covid-19 3.3% nasopharyngitis 3.3% NCT04937387 · Phase 3 · Asthma · phase 3 100/62.5/25 mcg nasopharyngitis 27.7% pharyngitis 10.6% bronchitis 8.5% NCT03184987 · Phase 3 · combination 100/62.5/25 mcg to 200/62.5/25 mcg bronchitis 22.2% dysgeusia 22.2% nasopharyngitis 22.2% NCT03184987 · Phase 3 · combination |
Notes
- aPopulation comparability has not been reviewed for 3 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
fluticasone furoate/umeclidinium/vilanterol
show 5 more results
show 3 more results
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Beclomethasone dipropionate/formoterol fumarate/glycopyrrolate's landscape · fluticasone furoate/umeclidinium/vilanterol's landscape